Muhammed Afolabi (MRC Gambia) received an ASTMH 2015 Annual Meeting Travel Award that is supported in part by the Bill & Melinda Gates Foundation.
The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance is delighted to announce to you its maiden Vaccine Pharmacovigilance Fellowship Programme. Deadline for registration is 21st August 2015. For enquiries kindly contact us at training [at] who-pvafrica [dot] org
EVI congratulates GlaxoSmithKline and PATH Malaria Vaccine Initiative (MVI) on their resounding success on the development of MosquirixTM, also known as RTS,S, for use in children aged six weeks to 17 months.
Dr. Michael Makanga will replace Professor Charles Mgone as Eecutive Director of The European & Developing Countries' Clinical Trials Partnership (EDCTP) in January 2016.
Dr. Makanga comes from a position as Head of EDCTP Africa Office in Cape Town, which he has held since 2008.
The Institute of Tropical Medicine and International Health in Berlin is offering a two week Advanced Vaccinology Course at Campus Virchow Klinikum CVK Charité, Berlin, 11-22 January 2016.
Acess flyer for more information and application form
A placental malaria vaccine R&D project from EVI (PRIMALVAC), funded by the Federal Ministry of Education and Research (BMBF), Germany is the subject of an article in the latest BMBF Health Research news letter. The article provides some background information about placental malaria, and summarises the approach followed in PRIMALVAC to develop a vaccine for this particular form of malaria. See page 10 “Malaria in der Schwangerschaft: Gefahr für Mutter und Kind".
The first EDUFLUVAC workshop on immunoassay standardisation for universal flu vaccines took place on 18-19 June 2015 at the National Institute for Biological Standards and Control (NIBSC), UK. This workshop was co-organised and co-sponsored by the National Institute of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID), USA.
BELLEROPHON would like to make a call for the process development and production in E. coli according to Good Manufacturing Practice (GMP) of a protein vaccine candidate to be used in toxicological and phase I studies. The subcontracting is expected in Q4 2015.
The annual meeting of MVVC / MVVC 2 held in Oxford in March is mentioned in the EDCTP May news letter (page 6). Field trials of a new combination malaria vaccine, which are an integral part of the MVVC2 project, are funded by among others EDCTP.
- 1 of 19